Summary of patient disposition in EXTEND (intent-to-treat population).^aPatients were considered to have completed this ongoing study if they were on study for at least 2 years and withdrew due to commercial availability of eltrombopag. ^bPatients may have had > 1 adverse event leading to withdrawal. ^cAccording to protocol specification. ^dOther adverse events leading to withdrawal were experienced by 1 patient each (Table 2). ^eOne of these patients, in the eltrombopag group and a responder in a prior study, withdrew due to other reason of “lack of response to drug.” Of these 30 patients, only 1 patient achieved platelets > 50 000/μL and > 2 × baseline without receiving rescue medication (1 platelet count of > 50 000/μL [54 000/μL], with baseline platelets of 15 000/μL). ^fOperation on cataract/lost to follow-up/protocol violation (n=1); lost effect of eltrombopag (n=1); stable platelets (n=1); Evan syndrome (n=1); pregnancy (n=1); and hemoglobin over the limit (n=1).